-
- Ruth E Board
- Discovery Medicine, AstraZeneca Pharmaceuticals, Macclesfield, UK
-
- Nicola J Thelwell
- DxS Ltd, Manchester, UK
-
- Paul F Ravetto
- DxS Ltd, Manchester, UK
-
- Stephen Little
- DxS Ltd, Manchester, UK
-
- Malcolm Ranson
- CRUK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
-
- Caroline Dive
- Clinical and Experimental Pharmacology Group, Paterson Institute of Cancer Research, University of Manchester, Manchester, UK
-
- Andrew Hughes
- Discovery Medicine, AstraZeneca Pharmaceuticals, Macclesfield, UK
-
- David Whitcombe
- DxS Ltd, Manchester, UK
書誌事項
- 公開日
- 2008-04-01
- 権利情報
-
- https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
- DOI
-
- 10.1373/clinchem.2007.098376
- 公開者
- Oxford University Press (OUP)
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p>Background: Mutations in the PIK3CA gene (phosphoinositide-3-kinase, catalytic, alpha polypeptide) have recently been described in a number of cancers, and their detection is currently limited because of the low sensitivity of conventional sequencing techniques.</jats:p> <jats:p>Methods: We combined Amplification Refractory Mutation System (ARMS™; AstraZeneca) allele-specific PCR and Scorpions™ (DxS) to develop assays for tumor-borne PIK3CA mutations and used real-time PCR to develop high-throughput multiplexed assays for the most commonly reported PIK3CA mutants (H1047L, H1047R, E542K, E545K).</jats:p> <jats:p>Results: These assays were more sensitive than sequencing and could detect 5 copies of mutant DNA in proportions as low as 0.1% of the total DNA. We assayed DNA extracted from human tumors and detected PIK3CA mutation frequencies of 10.2% in colorectal cancer, 38.7% in breast cancer, 1.9% in lung cancer, and 2.9% in melanoma. In contrast, sequencing detected only 53% of the mutations detected by our assay.</jats:p> <jats:p>Conclusions: Multiplexed assays, which can easily be applied to clinical samples, have been developed for the detection of PIK3CA mutations.</jats:p>
収録刊行物
-
- Clinical Chemistry
-
Clinical Chemistry 54 (4), 757-760, 2008-04-01
Oxford University Press (OUP)
